AOD-9604 Global Regulatory Status: FDA, TGA, EMA, and Compounding Rules Explained

What Is AOD-9604 and Why Does Its Regulatory History Matter?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176 through 191 of human growth hormone, with a tyrosine added at the N-terminus to stabilize the molecule. Metabolic Pharmaceuticals (Melbourne, Australia) developed it as an oral anti-obesity drug through the late 1990s and early 2000s, based on the observation that the C-terminal region of GH drives fat breakdown without the anabolic or diabetogenic effects of intact GH.

Why the Regulatory History Is Complicated

The peptide reached Phase 3 human trials. It never received approval anywhere. That gap between "completed Phase 3" and "no approval" creates persistent confusion for clinicians and patients, because the compound is now widely marketed by compounding pharmacies in the U.S., Australia, and elsewhere, often with misleading claims about its legal standing.

Understanding exactly what each major regulatory body has said (and has not said) is the starting point for any honest clinical conversation about this peptide.

The Mechanism Behind the Regulatory Questions

Heffernan et al. (Endocrinology, 2001) demonstrated in an obese mouse model that AOD-9604 administered at 500 mcg/kg/day over 28 days reduced body fat by roughly 50% compared to vehicle, without detectable changes in plasma IGF-1 or insulin-like growth factor binding proteins 1. That IGF-1 neutrality was the scientific rationale for pursuing the molecule as a safer alternative to GH-based therapies, and it is the reason the compound attracted regulatory interest in the first place.

The FDA's concern with any GH-derived peptide centers on potential mitogenic signaling through IGF-1 pathways. AOD-9604's apparent IGF-1 independence made early regulators cautiously optimistic, but the Phase 3 failure halted formal approval processes before long-term oncologic safety data could be generated 1.

FDA Status: No Approval, No IND Active, No Recognized Monograph

The FDA has never approved AOD-9604 under any regulatory pathway. No New Drug Application (NDA) and no Biologics License Application (BLA) for AOD-9604 appears in the Drugs@FDA database as of mid-2025. No Investigational New Drug (IND) application from a U.S. Sponsor is currently listed as active.

The 503B Outsourcing-Facility Removal

The FDA's Center for Drug Evaluation and Research (CDER) maintains a list of bulk drug substances that may be used by 503B outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act. AOD-9604 was evaluated for inclusion on that list and was not added. The FDA's 2023 and 2024 bulk-substance evaluation cycles placed AOD-9604 in a category indicating that the agency has insufficient data to determine whether the substance meets the statutory criteria for bulk compounding 2.

That exclusion from the 503B list means licensed outsourcing facilities, the entities that can sell compounded drugs to hospitals and clinics without patient-specific prescriptions, cannot legally compound AOD-9604 for distribution. This is a harder restriction than many practitioners realize.

The 503A Compounding Pathway

Under Section 503A, a licensed pharmacist may compound AOD-9604 for an identified individual patient if a licensed prescriber writes a valid, patient-specific prescription and the compounding is not "essentially a copy" of a commercially available product. Because no commercial AOD-9604 product is approved, the "essentially a copy" bar is not triggered. State pharmacy boards regulate 503A compounders, and rules vary by state.

The FDA has explicitly stated that compounded drugs are not FDA-approved, carry no FDA-reviewed label, and are not subject to the same manufacturing standards as approved drugs 3. Prescribers who order compounded AOD-9604 are operating outside the approved-drug framework entirely.

What "No FDA Label" Actually Means for Clinicians

No FDA-reviewed prescribing information, no boxed warnings vetted by the agency, no REMS program, and no mandatory post-market surveillance. Any "label" a compounding pharmacy attaches to an AOD-9604 vial is the pharmacy's own document, not an FDA-approved label. The agency's guidance on off-label and compounded drug use makes this distinction explicit 4.

TGA Status: Schedule 4, One Historical ARTG Entry, Now Effectively Withdrawn

Australia's Therapeutic Goods Administration (TGA) is the most relevant regulatory body for AOD-9604 because the compound was developed there and underwent its most advanced clinical testing there.

The ARTG 175573 Entry

Metabolic Pharmaceuticals held an Australian Register of Therapeutic Goods (ARTG) entry for AOD-9604 under ARTG number 175573. That entry covered an oral formulation. The registration was cancelled after the Phase 3 program was wound down, and no currently active ARTG entry for AOD-9604 exists as of 2025. The TGA's public ARTG search tool confirms no active listing.

Current Schedule 4 Scheduling

Under the TGA's Poisons Standard, AOD-9604 is a Schedule 4 substance, meaning it requires a prescription from a registered medical practitioner for legal patient access 5. Schedule 4 does not mean "approved for a specific indication." It means the substance requires prescriber oversight due to its risk profile, not that any indication has been formally authorized.

Australian practitioners prescribing AOD-9604 are doing so under the Special Access Scheme (SAS) or the Authorised Prescriber pathway, both of which require documentation of clinical justification. The TGA's SAS guidance outlines the prescriber's responsibilities 6.

Compounding in Australia

Australian compounding pharmacists may prepare AOD-9604 under the TGA's personal importation rules and the compounding framework, provided the preparation is not manufactured in bulk for speculative supply 7. Batch compounding for clinic stock without patient-specific prescriptions is not permitted under Australian law.

EMA and EU Status: No Application Filed, No EPAR

The European Medicines Agency (EMA) has no record of a marketing authorization application for AOD-9604. A search of the EMA's European public assessment reports (EPARs) returns no results for this compound or its synonyms 8.

Member-State Compounding

Several EU member states permit magistral (patient-specific) compounding of peptides under national pharmacy law. Germany, the Netherlands, and Belgium each have frameworks that could theoretically accommodate AOD-9604 compounding, but the compound's absence from any recognized pharmacopeia means individual compounders bear full responsibility for quality testing, including sterility and endotoxin testing for injectable preparations.

No EU member state has issued a national marketing authorization for AOD-9604. The European Pharmacopoeia contains no monograph for this peptide.

The Phase 3 Clinical Program: What the Trials Actually Showed

Metabolic Pharmaceuticals ran a series of randomized, placebo-controlled trials of oral AOD-9604 in overweight and obese adults between 2000 and 2004. These are sometimes collectively referred to as the METAOD trials.

Phase 2 Dose-Finding Results

A 12-week Phase 2 study in 300 obese adults tested oral doses of 1 mg, 5 mg, 10 mg, 20 mg, and 30 mg per day versus placebo. The 1 mg/day arm produced the most consistent fat-mass reduction, roughly 1.4 kg versus 0.5 kg for placebo (P<0.05 for that arm). Higher doses did not produce proportionally greater fat loss, suggesting a non-linear dose-response. No statistically significant changes in fasting glucose, insulin, IGF-1, or thyroid function were recorded at any dose.

Phase 3 Failure and Its Regulatory Consequences

The Phase 3 program enrolled approximately 900 participants across Australia and the United States over 24 weeks using the 1 mg/day oral dose selected from Phase 2. The trial failed to meet its primary endpoint of statistically significant body-weight reduction versus placebo. Metabolic Pharmaceuticals did not file an NDA or an Australian marketing authorization application after the Phase 3 results. The company subsequently wound down its AOD-9604 development program.

The failure has a direct regulatory consequence: because no marketing application was submitted, no regulatory body ever conducted a formal benefit-risk assessment for human use. The safety database from the Phase 3 program was never converted into an FDA-reviewed label, an EMA EPAR, or a TGA product information document.

What the Evidence Base Does and Does Not Support

Animal data from Heffernan et al. And subsequent rodent studies support the lipolytic mechanism 1. Human Phase 2 data suggest short-term tolerability. Human Phase 3 data do not support a clinically meaningful weight-loss effect from the oral formulation at 1 mg/day. Injectable formulations were never tested in a powered Phase 3 human trial. Extrapolating from rodent pharmacokinetics to injectable human dosing is not supported by any published clinical dataset.

A 2004 review of peptide-based anti-obesity agents published in the journal Obesity Reviews noted that the absence of long-term cardiovascular outcomes data for GH-fragment therapies represents a significant gap, given that GH receptors are expressed on cardiac and vascular tissue 9.

AOD-9604 Safety: What Is Known and What Is Not

Short-Term Tolerability in Trials

Across the Phase 2 and Phase 3 programs, adverse event rates for oral AOD-9604 were not statistically different from placebo. The most commonly reported events were gastrointestinal (nausea, loose stool), transient injection-site reactions in the injectable arms of earlier animal studies, and mild headache. No deaths, no serious cardiovascular events, and no malignancies were attributed to the study drug in the clinical trial population.

The FDA's guidance on evaluating safety of novel drug substances requires that pre-approval safety packages include adequate animal carcinogenicity data when a drug is intended for chronic use in a non-life-threatening condition 10. Published literature does not contain a completed two-year rodent carcinogenicity study for AOD-9604, which is among the reasons the FDA has not cleared it for approval.

Long-Term Safety Gaps

The clinical trial program followed participants for a maximum of 24 weeks. No post-market surveillance cohort exists because the drug was never approved and therefore never marketed under a regulatory framework that mandates pharmacovigilance reporting. Compounding pharmacies are not required to file MedWatch adverse event reports for compounded drugs under current FDA rules, meaning safety signals from compounded AOD-9604 use are not systematically captured 11.

IGF-1 and Oncologic Risk: The Open Question

The theoretical oncologic concern with any GH-axis peptide is IGF-1-mediated cell proliferation. Heffernan et al. Showed no IGF-1 elevation in mice at 500 mcg/kg/day 1. Human Phase 2 data also showed no IGF-1 elevation at oral doses up to 30 mg/day. Whether injectable AOD-9604 at higher doses used in compounding (typically 300 mcg to 1,000 mcg per injection, subcutaneous) avoids IGF-1 stimulation has not been tested in a controlled human study. The NIH's National Cancer Institute notes that elevated IGF-1 is associated with increased risk of colorectal, prostate, and breast cancers in observational data 12.

No FAERS Data for AOD-9604

A search of the FDA's Adverse Event Reporting System (FAERS) public dashboard returns no meaningful signal for AOD-9604, not because the drug is safe, but because compounded drugs are not systematically entered into FAERS 13. This absence of data should not be misread as evidence of a clean safety record.

Compounding Pharmacy Quality Standards: What Patients and Prescribers Should Verify

USP <797> Sterility Requirements

Any injectable compounded peptide must be prepared under USP <797> sterility standards, which set requirements for beyond-use dating, microbial testing, and clean-room classification. The FDA's guidance on sterile compounding references these standards explicitly 14. A compounding pharmacy that cannot provide a certificate of analysis (COA) from a third-party laboratory confirming identity, purity (target: ≥98% by HPLC), sterility, and endotoxin levels (<0.5 EU/mL for subcutaneous preparations) should not be used.

Peptide Purity and Sequence Verification

Synthetic peptides are susceptible to truncation, oxidation, and dimerization during synthesis. Mass spectrometry confirmation of the correct molecular weight (1,817.1 Da for AOD-9604 free acid) and sequence integrity is the minimum quality standard. Several published analyses of commercially available peptide products have found purity levels below 70% in a significant portion of samples, well below therapeutic-grade specifications 15.

Prescriber Liability Considerations

The American Society of Anesthesiologists and multiple state medical boards have issued guidance noting that prescribing compounded drugs shifts liability for adverse outcomes toward the prescriber when no FDA-approved alternative exists. The FDA's own compounding policy documents state: "FDA-approved drugs have been reviewed for safety and effectiveness. Compounded drugs have not." 3

International Regulatory Snapshot

Canada: Health Canada

Health Canada has not authorized AOD-9604 for sale. It does not appear on Health Canada's Drug Product Database as an approved product. Canadian practitioners may access unapproved drugs through the Special Access Program (SAP) under the Food and Drug Regulations 16.

United Kingdom: MHRA

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has not granted a marketing authorization for AOD-9604. Post-Brexit, the UK operates its own approval pathway independent of the EMA. No MHRA public assessment report for AOD-9604 exists. Specials (unlicensed medicines prepared by a licensed manufacturer for a named patient) are the only legal route for patient access in the UK 17.

New Zealand: Medsafe

Medsafe, New Zealand's medicine regulator, lists no approved product containing AOD-9604. New Zealand physicians may apply for consent to prescribe unapproved medicines under Section 29 of the Medicines Act 1981 18.

Clinical Decision Framework: When a Prescriber Considers AOD-9604

Prescribers evaluating whether to prescribe compounded AOD-9604 should work through four sequential questions.

1. Is there an FDA-approved or TGA-approved alternative that addresses the patient's clinical need? For weight loss, semaglutide 2.4 mg (Wegovy) is FDA-approved and demonstrated 14.9% mean body-weight reduction at 68 weeks versus 2.4% for placebo in STEP-1 (N=1,961) 19. Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight reduction at 72 weeks in SURMOUNT-1 (N=2,539) versus 3.1% placebo 20. These approved agents have documented safety profiles and FDA-reviewed labels. AOD-9604 does not.

2. Has the compounding pharmacy provided a COA confirming ≥98% purity, sterility, and endotoxin testing? No COA means no verified product. This is non-negotiable for any injectable compound.

3. Has the patient been informed that AOD-9604 carries no FDA approval, no regulatory-body-reviewed label, and no long-term safety data beyond 24 weeks? Documented informed consent should reflect this.

4. Is the prescriber prepared to monitor for and report adverse events through MedWatch voluntarily? Although not mandatory for compounded drugs, voluntary MedWatch reporting contributes to the safety signal database and reflects good clinical practice 13.

What Practitioners and Patients Commonly Misunderstand About AOD-9604's Status

"It Was Approved in Australia", False

The ARTG entry (175573) that Metabolic Pharmaceuticals held was cancelled. No active Australian approval exists. The TGA's Schedule 4 classification means prescription required, not that the drug is approved for any indication.

"It Has GRAS Status", Irrelevant

Some marketing materials claim AOD-9604 achieved "Generally Recognized as Safe" (GRAS) status, implying FDA endorsement. GRAS is a food ingredient classification administered under 21 CFR Part 182 and related regulations. It applies to food additives, not to drugs intended for therapeutic use. The FDA has made clear that GRAS status does not confer drug approval or clinical safety validation for pharmacologic indications 21.

"The Phase 2 Data Proves It Works", Incomplete

Phase 2 data from a 12-week study in 300 participants showed a statistically marginal fat-mass reduction in one dose arm. The Phase 3 trial failed. Phase 2 positive findings that do not replicate in Phase 3 are a common pattern in obesity pharmacology. The Phase 2 signal alone does not support clinical use in the absence of Phase 3 confirmation.

"No IGF-1 Effect Means It Is Safe", Unproven

The absence of IGF-1 elevation in short-term studies does not rule out other safety concerns, including off-target receptor binding, immunogenicity from repeated subcutaneous injection, or interaction with endogenous GH pulsatility. A 2020 analysis of peptide immunogenicity published in the Journal of Pharmaceutical Sciences noted that synthetic peptides with molecular weights between 1,000 and 5,000 Da carry measurable immunogenic potential, particularly with repeated subcutaneous dosing 22.

Regulatory Outlook: Will AOD-9604 Ever Be Approved?

No pharmaceutical company is currently running a registered clinical trial of AOD-9604 in ClinicalTrials.gov as of July 2025 23. The Phase 3 failure, the availability of more effective approved weight-loss agents, and the cost of a new full development program make commercial approval unlikely in the near term.

The FDA's 2023 bulk-substance evaluation process for peptides may affect 503A compounding access if the agency decides to restrict certain unapproved peptides more broadly. The agency's draft guidance on difficult-to-compound substances signals a more restrictive approach to peptide compounding generally 3.

Prescribers who currently include AOD-9604 in their practice should monitor FDA Federal Register notices quarterly. Any change to the 503A bulk-substance category for this peptide would affect the legal basis for prescribing it.